Buchumschlag

Blood Pressure Status Modulates the Therapeutic Response to Sodium‐Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Ryoichi Ishibashi, Masaya Koshizaka, Yoko Takatsuna, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Journal of Diabetes
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial
von: Yoko Takatsuna, et al.
Veröffentlicht: (2026)

Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post‐hoc Analysis of the COMET Trial
von: Ryoichi Ishibashi, et al.
Veröffentlicht: (2026)

Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial
von: Tomoaki Tatsumi, et al.
Veröffentlicht: (2025)

Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
von: Kiichi Hirayama, et al.
Veröffentlicht: (2025)

Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
von: Takuya Oyakawa, et al.
Veröffentlicht: (2024)

Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis
von: Jiayang Lin, et al.
Veröffentlicht: (2026)

Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients
von: Emili Anderson, et al.
Veröffentlicht: (2025)

Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation
von: Ghee Kheng Lim, et al.
Veröffentlicht: (2025)

Factors That Influence Blood Pressure Changes With the Use of Sodium‐Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes
von: Sara Salama, et al.
Veröffentlicht: (2026)

Commentary on “Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation”
von: Pouya Tayebi, et al.
Veröffentlicht: (2025)

Target Trial Emulations of Sodium‐Glucose Cotransporter 2 Inhibitors in Systemic Lupus Erythematosus
von: Janet Pope, et al.
Veröffentlicht: (2025)

Blood Pressure Reduction and Changes in Antihypertensive Medication Use Among Patients With Hypertension Who Initiated Sodium‐Glucose Cotransporter‐2 Inhibitors
von: Jaejin An, et al.
Veröffentlicht: (2024)

Letter to the Editor: Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation
von: Syed Ali Raza Zaidi, et al.
Veröffentlicht: (2025)

Reconsidering the Antiarrhythmic Role of Sodium–Glucose Cotransporter‐2 Inhibitors After Atrial Fibrillation Ablation
von: Muhammet Cihat Çelik, et al.
Veröffentlicht: (2025)

Impaired insulin receptor function alters psychiatric behaviors without affecting circadian rhythms in a mouse model of Alzheimer's disease
von: Naotaka Izuo, et al.
Veröffentlicht: (2025)

Kidney Effects of Finerenone Added to Sodium‐Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease
von: Qing Yang, et al.
Veröffentlicht: (2026)

Response to Letter Regarding “Sodium–Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation”
von: Xuan Ci Mee, et al.
Veröffentlicht: (2025)

Sodium‐Glucose Cotransporter 2 Inhibitors Use and Adverse Kidney Outcomes in Patients Receiving Contrast Media
von: Lung‐Chih Li, et al.
Veröffentlicht: (2025)

Predictors of Discontinuation of Angiotensin Converting Enzyme Inhibitors Use Among Medicare Beneficiaries Using Sodium‐Glucose Cotransporter 2 Inhibitors
von: Hongjie Qian, et al.
Veröffentlicht: (2026)

A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema
von: Quinty Bisseling, et al.
Veröffentlicht: (2026)

Association Between Sodium–Glucose Cotransporter‐2 Inhibitors and Sepsis Risk in Patients With Type 2 Diabetes Mellitus
von: Chun-Ying Wu, et al.
Veröffentlicht: (2026)

Response to Letter to the Editor Concerning the Article “Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation”
von: Ramzi Ibrahim, et al.
Veröffentlicht: (2025)

Correction to “Association Between Sodium–Glucose Cotransporter‐2 Inhibitors and Sepsis Risk in Patients With Type 2 Diabetes Mellitus”
Veröffentlicht: (2026)

Two Birds With One Stone: The Protective Role of the Antidiabetic Drug Sodium‐Glucose Cotransporter‐2 Inhibitor in Neurodegenerative Diseases
von: LiRong Zhang, et al.
Veröffentlicht: (2025)

Clinical obesity and Himan‐sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesity care
von: Wataru Ogawa, et al.
Veröffentlicht: (2025)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
von: Cheng‐Hsien Hung, et al.
Veröffentlicht: (2025)

Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With or Without Metabolic Syndrome
von: Yang Xu, et al.
Veröffentlicht: (2025)

Gender Bias in Clinical Trials of Sodium–Glucose Cotransporter 2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review
von: Santiago José Lora-Escobar, et al.
Veröffentlicht: (2025)

Renal Protection at a Metabolic Cost: A Systematic Review and Meta‐Analysis of Perioperative Use of Sodium–Glucose Cotransporter 2 Inhibitors
von: Elsayed Balbaa, et al.
Veröffentlicht: (2026)

Deletion of the Sodium Glucose Cotransporter 1 (Sglt‐1) impairs mouse sperm movement
von: September Numata, et al.
Veröffentlicht: (2024)

Deranged Mineral Balance Exacerbated by Concomitant Use of Licorice and Sodium–Glucose Cotransporter‐2 Inhibitor in an Older Subject With Impaired Activities of Daily Living
von: Hiroya Kitsunai, et al.
Veröffentlicht: (2025)

Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy
von: Maharan Kabha, et al.
Veröffentlicht: (2025)

Development of a 671 nm injection-locked CW Ti:sapphire laser
von: Yamamoto, Yoko, et al.
Veröffentlicht: (2022)

Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double‐Blind Randomized Crossover Placebo‐Controlled Trial
von: Mayumi Shoji, et al.
Veröffentlicht: (2025)

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial
von: Koutaro Yokote, et al.
Veröffentlicht: (2025)

Posterior Microphthalmos With RPE Dysfunction Misdiagnosed as Macular Edema
von: Xiaping Wang, et al.
Veröffentlicht: (2025)

Clinical Outcomes in Type 2 Diabetes Patients After Acute Myocardial Infarction: A Comparison of Sodium–Glucose Cotransporter 2 Inhibitors vs. Non‐Users
von: Hsin‐Fu Lee, et al.
Veröffentlicht: (2024)

Cardiorenal Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic‐Range Proteinuria: A Multi‐Institutional Target Trial Emulation
von: Jia‐Jin Chen, et al.
Veröffentlicht: (2026)

Recommendations for cancer screening and surveillance in patients with Werner syndrome
von: Kazuto Aono, et al.
Veröffentlicht: (2024)

A Highly Sensitive Inclusion Complex Based Spectrofluorimetric Method for the Determination of Certain Sodium Glucose Cotransporter‐2 Inhibitors: Greenness Assessment and Application to Different Biological Fluids
von: Doaa H. Rushdy, et al.
Veröffentlicht: (2024)